Small Intestine Cancer

Small intestine cancer, also known as small bowel cancer, refers to the abnormal growth of cells in the tissues of the small intestine. As a pioneer in the gastrointestinal cancer field, Alfa Cytology provides a complete solution for small intestine cancer.

Incidence and Mortality of Small Intestine Cancer

Estimated new cases and deaths from small intestine cancer in the United States in 2024:

• New cases: 12,440.
• Deaths: 2,090.

Small intestine cancer types include adenocarcinoma, sarcoma, neuroendocrine tumor, gastrointestinal stromal tumor, and lymphoma. Small intestine cancer accounts for 3.5% of all digestive system malignancies.

Therapy Development for Small Intestine Cancer

Small intestine cancer therapeutics market size is estimated to reach $10.6 billion by 2027, growing at a CAGR of 7.3% during the forecast period 2022-2027. Small intestine cancer therapeutics involves surgery, radiation therapy and chemotherapy. The greater per capita expenditure on healthcare and the launch of novel oncological medications are set to propel the growth of the small intestine cancer therapeutics industry during the forecast period 2022-2027. This represents the small intestine cancer therapeutics industry outlook.

Our Services

Alfa Cytology is devoted to developing more effective and personalized therapy for small intestine cancer. We provide one-stop solutions for small intestine cancer, including but not limited to the following.

Therapeutics Development Services

Small Molecule Drug
Cell Therapy
Gene Therapy

Diagnostic Development Services

Cancer Biomarker Discovery
Imaging Services
Multi-omics Services

Preclinical Research Services

Molecular Biology Services
Tumorigenesis Analysis
Cancer Metabolism Analysis

Modeling Services of Small Intestine Cancer

Animal Models

Xenograft Models

• Patient-Derived Xenograft (PDX) Model
• Cell Line Xenograft (CDX) Model

Genetically Engineered Mouse Models (GEMMs)

Cell Line Models

• HCT-8
• NCI-H716
• SW948
• SNU-1

Organoids

Derived from:

• Patient Tumor Samples
• Induced Pluripotent Stem Cells (iPSCs)

Optional Species

• Mouse
• Rats
• Zebrafish
• Non-human Primates
• Others

Alfa Cytology is committed to the research and study of cancer, from cell therapy development services, immune checkpoint inhibitor development services, to cancer drug development services, providing one-stop solutions. Our cancer experts have many years of experience in the development of the latest therapies for small intestine cancer. If you are interested in our service, please contact us.

For research use only.